| Cytokine release syndrome A Shimabukuro-Vornhagen, P Gödel, M Subklewe, HJ Stemmler, ... Journal for immunotherapy of cancer 6, 1-14, 2018 | 1579 | 2018 |
| Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells K Inaba, S Turley, F Yamaide, T Iyoda, K Mahnke, M Inaba, M Pack, ... The Journal of experimental medicine 188 (11), 2163-2173, 1998 | 809 | 1998 |
| Structures of the human and Drosophila 80S ribosome AM Anger, JP Armache, O Berninghausen, M Habeck, M Subklewe, ... Nature 497 (7447), 80-85, 2013 | 646 | 2013 |
| Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia KH Metzeler, T Herold, M Rothenberg-Thurley, S Amler, MC Sauerland, ... Blood, The Journal of the American Society of Hematology 128 (5), 686-698, 2016 | 596 | 2016 |
| Advances in cancer immunotherapy 2019–latest trends S Kruger, M Ilmer, S Kobold, BL Cadilha, S Endres, S Ormanns, ... Journal of Experimental & Clinical Cancer Research 38, 1-11, 2019 | 567 | 2019 |
| The DNA inflammasome in human myeloid cells is initiated by a STING-cell death program upstream of NLRP3 MM Gaidt, TS Ebert, D Chauhan, K Ramshorn, F Pinci, S Zuber, F O’Duill, ... Cell 171 (5), 1110-1124. e18, 2017 | 530 | 2017 |
| KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study BD Shah, A Ghobadi, OO Oluwole, AC Logan, N Boissel, RD Cassaday, ... The Lancet 398 (10299), 491-502, 2021 | 521 | 2021 |
| Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion J Engelmayer, M Larsson, M Subklewe, A Chahroudi, WI Cox, ... The Journal of Immunology 163 (12), 6762-6768, 1999 | 465 | 1999 |
| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 418 | 2021 |
| Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1 C Münz, KL Bickham, M Subklewe, ML Tsang, A Chahroudi, MG Kurilla, ... The Journal of experimental medicine 191 (10), 1649-1660, 2000 | 401 | 2000 |
| A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells A Reddy, M Sapp, M Feldman, M Subklewe, N Bhardwaj Blood, The Journal of the American Society of Hematology 90 (9), 3640-3646, 1997 | 317 | 1997 |
| Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML S Haubner, F Perna, T Köhnke, C Schmidt, S Berman, C Augsberger, ... Leukemia 33 (1), 64-74, 2019 | 282 | 2019 |
| CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ... Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513, 2021 | 275 | 2021 |
| Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism C Krupka, P Kufer, R Kischel, G Zugmaier, FS Lichtenegger, T Köhnke, ... Leukemia 30 (2), 484-491, 2016 | 271 | 2016 |
| Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the … PJ Hayden, C Roddie, P Bader, GW Basak, H Bonig, C Bonini, ... Annals of oncology 33 (3), 259-275, 2022 | 256 | 2022 |
| CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330 C Krupka, P Kufer, R Kischel, G Zugmaier, J Bögeholz, T Köhnke, ... Blood, The Journal of the American Society of Hematology 123 (3), 356-365, 2014 | 239 | 2014 |
| Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP … RU Trappe, D Dierickx, H Zimmermann, F Morschhauser, P Mollee, ... Journal of Clinical Oncology 35 (5), 536-543, 2017 | 208 | 2017 |
| Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia T Herold, M Rothenberg-Thurley, VV Grunwald, H Janke, D Goerlich, ... Leukemia 34 (12), 3161-3172, 2020 | 202 | 2020 |
| Features of human CD3+ CD20+ T cells E Schuh, K Berer, M Mulazzani, K Feil, I Meinl, H Lahm, M Krane, ... The Journal of Immunology 197 (4), 1111-1117, 2016 | 201 | 2016 |
| Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells FS Lichtenegger, M Rothe, FM Schnorfeil, K Deiser, C Krupka, ... Frontiers in immunology 9, 385, 2018 | 186 | 2018 |
